Myotonic Dystrophy News and Research

RSS
Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis Pharmaceuticals announces initiation of ISIS-SMN Rx Phase 3 study in children with SMA

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis receives $10 million from Biogen Idec to initiate IND-supporting studies of ISIS-BIIB3 Rx

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Isis Pharmaceuticals provides update on Phase 2 clinical studies of ISIS-SMN Rx in children with SMA

Research could help eventual treatment of degenerative muscle, brain diseases

Research could help eventual treatment of degenerative muscle, brain diseases

New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy

New approach to turn diseased cells into unique manufacturing sites for treating muscular dystrophy

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Researchers use RNA sequencing to look at early- and late-stage development of the heart

Researchers use RNA sequencing to look at early- and late-stage development of the heart

U.Va. researchers named recipients of 2013 Hartwell Individual Biomedical Research Awards

U.Va. researchers named recipients of 2013 Hartwell Individual Biomedical Research Awards

Isis Pharmaceuticals provides update on ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals provides update on ISIS-SMNRx Phase 2 study in infants with SMA

Scientists reveal atomic-level view of genetic defect that causes myotonic dystrophy type 2

Scientists reveal atomic-level view of genetic defect that causes myotonic dystrophy type 2

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Stem cell lines are ideal research tools for designing models to understand disease progression

Stem cell lines are ideal research tools for designing models to understand disease progression

Researchers identify likely molecular pathway that causes untreatable neurodegenerative diseases

Researchers identify likely molecular pathway that causes untreatable neurodegenerative diseases

Scientists identify RNA regulator that plays critical role in proper functioning of hESCs

Scientists identify RNA regulator that plays critical role in proper functioning of hESCs

Novel way to dramatically raise potency of drug candidates targeting RNA

Novel way to dramatically raise potency of drug candidates targeting RNA

TSRI scientists identify small molecules to control genetic defect responsible for muscular dystrophy

TSRI scientists identify small molecules to control genetic defect responsible for muscular dystrophy

New hope for patients with myotonic dystrophy

New hope for patients with myotonic dystrophy

Clinical trial signals new era in treatment of neurodegererative disorders

Clinical trial signals new era in treatment of neurodegererative disorders